Ultrasound-guided treatment for outpatients with heart failure
Tests ultrasound-guided heart failure treatment in adult outpatients with heart failure.
Plain-language title generated from the registry record
Registry title: AMBulatory UltraSound for Heart Failure Management
Key facts
- Where
- Besançon, Mulhouse, Reims, Thionville, and Vandœuvre-lès-Nancy, FranceSee the 5 sites
Where in France
- CHU de BesançonBesançon, FranceNot yet recruiting
- CH de MulhouseMulhouse, FranceNot yet recruiting
- CHRU de ReimsReims, FranceNot yet recruiting
- CHR de MetzThionville, FranceNot yet recruiting
- CHRU de NancyVandœuvre-lès-Nancy, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Central Hospital, Nancy, France
- Trial code
- NCT04741711
- Record updated
- 17 May 2023
- Original description
AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE (Prospective Randomized Open Blinded End-point) type).Read full original descriptionShow less
Impact of Ultrasound-guided Therapeutic Management of Ambulatory Patients With Heart Failure : An Open-label Randomized Clinical Trial
AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE (Prospective Randomized Open Blinded End-point) type).
The main objective of AMBUSH study is to assess the effect of therapeutic management guided by pulmonary ultrasound and the assessment of the inferior vena cava in patients with heart failure seen in an ambulatory (outpatient) setting on a mixed clinical-biological endpoint (including variations of natriuretic peptides - NtProBNP) at 30 days.
Inclusion: Male or female aged 18 and over; Heart failure (regardless of left ventricular ejection fraction); Diagnosis of heart failure established more than 3 months ago; Absence of significant clinical signs of congestion on clinical examination (absence of crackles and lower limbs oedema greater than perimalleolar oedema); Affiliation to social security; Receiving complete information about research organization and signed informed consent.
Exclusion: Natriuretic peptides result, carried out during the previous 30 days, available at the inclusion consultation; Suspicion of cardiac amyloidosis or proven amyloidosis,; Patient with severe primary heart valve disease; Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code; Pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis; Pregnant woman, parturient or nursing mother; Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice); Person deprived of liberty by a judicial or administrative decision,.